XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2
REVENUE
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2024202320242023
Screening
Medicare Parts B & C$195,337 $176,016 $369,127 $347,746 
Commercial283,729 245,748 537,872 478,781 
Other52,540 41,023 99,405 79,455 
Total Screening531,606 462,787 1,006,404 905,982 
Precision Oncology
Medicare Parts B & C$47,467 $47,588 $95,517 $94,969 
Commercial49,187 46,212 95,887 91,144 
International46,722 35,586 91,255 72,854 
Other24,282 27,788 47,725 53,639 
Total Precision Oncology167,658 157,174 330,384 312,606 
COVID-19 Testing$— $2,132 $— $5,955 
Total$699,264 $622,093 $1,336,788 $1,224,543 
Screening revenue primarily includes laboratory service revenue from Cologuard and Prevention Genetics, LLC (“PreventionGenetics”) tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2024. Adjustments to revenue recognized during the period relating to prior period estimates were less than 2% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2023.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not significant as of June 30, 2024 and December 31, 2023.
Revenue recognized for the three and six months ended June 30, 2024 and 2023 that was included in the deferred revenue balance at the beginning of the period was not significant.